Abstract
The measles–mumps–rubella (MMR) vaccine is currently the exclusive tool for the prevention of measles, mumps, and rubella in Europe. The description below of single measles, mumps, and rubella vaccines is given for historical reasons and for the characterization of their properties as components of the MMR vaccine. Previous immunization programs with single vaccines, usually given as a single dose, were generally less effective than the current MMR immunization programs in early childhood, with the vaccine given in two doses.
A full description of measles, mumps, and rubella diseases is beyond the scope of this chapter. In the following, the description of the manifestations and the burden of these diseases is limited to make the argument in favor of immunization. With the success of the MMR vaccination programs in some European countries, the respective diseases are seldom seen, and the rationale for vaccination may be forgotten or not appreciated by the public and healthcare personnel. In many European countries, outbreaks of measles and rubella continue to occur.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Bolotovski V, et al. Immunization of 6 and 9 month old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine. Int J Epidemiol. 1994;23(5):1069–77.
Bottiger M, et al. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps and rubella. BMJ. 1987;295:1264–7.
Davis NF, et al. The increasing incidence of mumps orchitis: a comprehensive review. BJU Int. 2010;105(8):1060–5.
Edmunds WJ, et al. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol Infect. 2000;125(3):635–50.
Enders J. Measles virus. Historical review, isolation, and behavior in various systems. Am J Dis Child. 1962;103:282–7.
Enders JF, Peebles TC. Propagation in tissue cultures of cytopathic agents from patients with measles. Proc Soc Exp Biol Med. 1954;86:277–86.
Fidel PL, Noverr MC. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection? Bio 2020;11e.00907-20.
Garenne M, et al. Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet. 1991;338(8772):903–7.
Hörner C et al. A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 Vaccine. bioRxiv preprint. https://doi.org/10.1101/2020.07.11.198291.
Ikić DM. Edmonston-Zagreb strain of measles vaccine: epidemiologic evaluation in Yugoslavia. Rev Infect Dis. 1983;5(3):558– 63.
Immunization Safety Review Committee, Immunization safety review. Vaccines and autism. 2004, Washington, DC: National Academies Press. p. 214.
Klein N, Fireman B, Yih K, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010;126(1):e1–8.
Lievano F, et al. Measles, mumps, and rubella virus vaccine (M–M–R™II): a review of 32 years of clinical and postmarketing experience. Vaccine. 2012;30(48):6918–26.
Mercader S, Garcia P, Bellini WJ. Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings. Clin Vaccine Immunol 2012;19:1810–1817.
Peltola H, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med. 1994;331(21):1397–402.
Peltola H, et al. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis. 2008;8:796–803.
Plotkin SA. The history of rubella and rubella vaccination leading to elimination. Clin Infect Dis. 2006;43(Suppl 3):S164–8.
Plotkin S, Mortimer E. Vaccines. second ed. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: W.B. Saunders Company; 1994.
Plotkin SA, et al. Attenuation of RA27/3 rubella virus in WI-38 human diploid cells. Am J Dis Child. 1969;118:178–85.
Sidiq KR, Sabir DK, Shakhawan MA, Kodzius R. Does Early Childhood Vaccination Protect Against COVID-19? Front Mol Biosci 2020;7:120.
Stratton K, et al. Measles-mumps-rubella vaccine and autism. Immunization Safety Review. National Academy Press, Washington, DC; 2001.
Usonis V, et al. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children. Infection. 1998;26(4):222–6.
Usonis V, et al. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J. 1999;18(1):42–8.
Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J. 2007;26(7):632–8.
Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637–41.
WHO Euro. Measles and rubella elimination. Package for accelerated action 2013–2015.
WHO Position Paper. Mumps virus vaccines. Wkly Epidemiol Rec. 2007;82(7):51–60.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Vesikari, T., Usonis, V. (2021). Measles–Mumps–Rubella Vaccine. In: Vesikari, T., Van Damme, P. (eds) Pediatric Vaccines and Vaccinations. Springer, Cham. https://doi.org/10.1007/978-3-030-77173-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-77173-7_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-77172-0
Online ISBN: 978-3-030-77173-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)